Figure A12.
Risk ratio for respiratory syncytial virus (RSV) vaccines in older adults (age ≥ 60 years) with lower respiratory tract disease (LRTD) with 3 or more signs/symptoms in serogroup A vs. serogroup B (I2 0.0%, 95% CI 0.0 to 89.6; tau2 0.0, 95% CI 0.0 to 7.469; Q = 0.31, p = 0.856) [51,52,81].